stockportfolio.pro
Stocks / GRDN vs RCUS
GRDN vs RCUS
Guardian Pharmacy Services, Inc. and Arcus Biosciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Guardian Pharmacy Services, Inc. (GRDN) | Arcus Biosciences, Inc. (RCUS) | |
|---|---|---|
| Market cap | $2.7B | $2.8B |
| Revenue (latest FY) | $1.45B | $247.00M |
| Net income (latest FY) | $49.22M | $-353.00M |
| Revenue growth (5y CAGR) | 16.8% | 25.9% |
| Net margin | 3.4% | -142.9% |
| Return on equity | 23.9% | -55.9% |
| P/E ratio | 50.1 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 1 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open GRDN — free Open RCUS — freeFrequently asked questions
Which is bigger, GRDN or RCUS?
Arcus Biosciences, Inc. is larger by market capitalization — $2.8B versus $2.7B.
Which grows faster, GRDN or RCUS?
Over the last five fiscal years, Arcus Biosciences, Inc. grew revenue faster — 25.9%/yr versus 16.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.